RU2007147346A - Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний - Google Patents
Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний Download PDFInfo
- Publication number
- RU2007147346A RU2007147346A RU2007147346/04A RU2007147346A RU2007147346A RU 2007147346 A RU2007147346 A RU 2007147346A RU 2007147346/04 A RU2007147346/04 A RU 2007147346/04A RU 2007147346 A RU2007147346 A RU 2007147346A RU 2007147346 A RU2007147346 A RU 2007147346A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- formula
- aryl
- compound
- alkoxy
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims 4
- 235000012000 cholesterol Nutrition 0.000 title claims 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 27
- 125000003118 aryl group Chemical group 0.000 claims abstract 21
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 19
- 239000001257 hydrogen Substances 0.000 claims abstract 19
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 11
- 150000003839 salts Chemical class 0.000 claims abstract 8
- 239000012453 solvate Substances 0.000 claims abstract 8
- -1 hydroxy, amino, guanidino, cyano, carbamoyl Chemical group 0.000 claims abstract 7
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 6
- 125000001475 halogen functional group Chemical group 0.000 claims abstract 5
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 4
- 239000000651 prodrug Substances 0.000 claims abstract 4
- 229940002612 prodrug Drugs 0.000 claims abstract 4
- 125000001424 substituent group Chemical group 0.000 claims abstract 4
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 238000000034 method Methods 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 230000003993 interaction Effects 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims 1
- RCPFYNVPTYWLDB-FBYGKGGKSA-N 2-[[(2r)-3-cyclohexyl-2-[[2-[[2-[4-[(2r,3r)-3-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxyethyl]sulfanyl-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy]acetyl]amino]acetyl]amino]propanoyl]amino]acetic acid Chemical compound N1([C@@H]([C@H](C1=O)SCC(O)C=1C=C2OCCOC2=CC=1)C=1C=CC(OCC(=O)NCC(=O)N[C@H](CC2CCCCC2)C(=O)NCC(O)=O)=CC=1)C1=CC=C(F)C=C1 RCPFYNVPTYWLDB-FBYGKGGKSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 108010028924 PPAR alpha Proteins 0.000 claims 1
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000007257 deesterification reaction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000003614 peroxisome proliferator Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 0 CC(*)(C(O)=O)N(*)C(C(*)(*)NC)=O Chemical compound CC(*)(C(O)=O)N(*)C(C(*)(*)NC)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0501468-3 | 2005-06-22 | ||
| SE0501468 | 2005-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007147346A true RU2007147346A (ru) | 2009-07-27 |
Family
ID=37570731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007147346/04A RU2007147346A (ru) | 2005-06-22 | 2006-06-21 | Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100048530A1 (enExample) |
| EP (1) | EP1896458A4 (enExample) |
| JP (1) | JP2008546770A (enExample) |
| KR (1) | KR20080033265A (enExample) |
| CN (1) | CN101223163A (enExample) |
| AR (1) | AR057383A1 (enExample) |
| AU (1) | AU2006259894A1 (enExample) |
| BR (1) | BRPI0611616A2 (enExample) |
| CA (1) | CA2609990A1 (enExample) |
| EC (1) | ECSP088103A (enExample) |
| IL (1) | IL187738A0 (enExample) |
| MX (1) | MX2007016486A (enExample) |
| NO (1) | NO20076196L (enExample) |
| RU (1) | RU2007147346A (enExample) |
| TW (1) | TW200726760A (enExample) |
| UY (1) | UY29615A1 (enExample) |
| WO (1) | WO2006137793A1 (enExample) |
| ZA (1) | ZA200710606B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| JP4688819B2 (ja) * | 2003-12-23 | 2011-05-25 | アストラゼネカ アクチボラグ | コレステロール吸収阻害活性を有するジフェニルアゼチジノン誘導体 |
| UY29607A1 (es) * | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
| MY148538A (en) * | 2005-06-22 | 2013-04-30 | Astrazeneca Ab | Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
| AR054482A1 (es) * | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | Derivados de azetidinona para el tratamiento de hiperlipidemias |
| AR057380A1 (es) * | 2005-06-22 | 2007-11-28 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos |
| SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| AR060623A1 (es) * | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
| AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
| PE20081877A1 (es) * | 2007-03-06 | 2008-12-27 | Teijin Pharma Ltd | Derivado de la 1,4-diarilacetidinona |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| US9212175B2 (en) | 2009-03-06 | 2015-12-15 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
| JP2013503135A (ja) | 2009-08-26 | 2013-01-31 | サノフイ | 新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用 |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| KR20230158005A (ko) | 2021-03-18 | 2023-11-17 | 씨젠 인크. | 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3300B (en) * | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
| US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US7053080B2 (en) * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| DE60229406D1 (de) * | 2001-09-21 | 2008-11-27 | Schering Corp | Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en) |
| GB0215579D0 (en) * | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| US6761509B2 (en) * | 2002-07-26 | 2004-07-13 | Jan Erik Jansson | Concrete module for retaining wall and improved retaining wall |
| US6960047B2 (en) * | 2002-08-02 | 2005-11-01 | Innovative Technology Application, Inc. | Protection barrier apparatus |
| EP1601668B1 (en) * | 2003-03-07 | 2008-08-27 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| US7002008B2 (en) * | 2003-06-16 | 2006-02-21 | Bomi Patel Framroze | Process for the preparation of 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-azetidin-2-one |
| WO2005046797A2 (en) * | 2003-11-05 | 2005-05-26 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
| AU2004308332B2 (en) * | 2003-12-23 | 2008-04-10 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
| GB0329778D0 (en) * | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
| JP4688819B2 (ja) * | 2003-12-23 | 2011-05-25 | アストラゼネカ アクチボラグ | コレステロール吸収阻害活性を有するジフェニルアゼチジノン誘導体 |
| KR100725758B1 (ko) * | 2004-03-30 | 2007-06-08 | 삼성광주전자 주식회사 | 전동 송풍기 및 이를 이용한 자동차용 전동 과급기 |
| US20060046996A1 (en) * | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
| EP1807070A1 (en) * | 2004-09-29 | 2007-07-18 | Schering Corporation | Combinations of substituted azetidinones and cb1 antagonists |
| SA06270191B1 (ar) * | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| AR054482A1 (es) * | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | Derivados de azetidinona para el tratamiento de hiperlipidemias |
| US20070049748A1 (en) * | 2005-08-26 | 2007-03-01 | Uppala Venkata Bhaskara R | Preparation of ezetimibe |
| TW200806623A (en) * | 2005-10-05 | 2008-02-01 | Merck & Co Inc | Anti-hypercholesterolemic compounds |
| US7498431B2 (en) * | 2005-12-01 | 2009-03-03 | Bomi Patel Framroze | Process for the preparation of chiral azetidinones |
| AR060623A1 (es) * | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
| EP2066668A1 (en) * | 2006-09-15 | 2009-06-10 | Schering Corporation | Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders |
| PE20081877A1 (es) * | 2007-03-06 | 2008-12-27 | Teijin Pharma Ltd | Derivado de la 1,4-diarilacetidinona |
-
2006
- 2006-06-20 AR ARP060102615A patent/AR057383A1/es not_active Application Discontinuation
- 2006-06-21 UY UY29615A patent/UY29615A1/es not_active Application Discontinuation
- 2006-06-21 AU AU2006259894A patent/AU2006259894A1/en not_active Abandoned
- 2006-06-21 JP JP2008518084A patent/JP2008546770A/ja not_active Withdrawn
- 2006-06-21 RU RU2007147346/04A patent/RU2007147346A/ru not_active Application Discontinuation
- 2006-06-21 EP EP06747951A patent/EP1896458A4/en not_active Withdrawn
- 2006-06-21 MX MX2007016486A patent/MX2007016486A/es not_active Application Discontinuation
- 2006-06-21 CA CA002609990A patent/CA2609990A1/en not_active Abandoned
- 2006-06-21 KR KR1020087001049A patent/KR20080033265A/ko not_active Withdrawn
- 2006-06-21 US US11/993,479 patent/US20100048530A1/en not_active Abandoned
- 2006-06-21 CN CNA2006800262826A patent/CN101223163A/zh active Pending
- 2006-06-21 WO PCT/SE2006/000762 patent/WO2006137793A1/en not_active Ceased
- 2006-06-21 BR BRPI0611616-7A patent/BRPI0611616A2/pt not_active Application Discontinuation
- 2006-06-22 TW TW095122510A patent/TW200726760A/zh unknown
-
2007
- 2007-11-28 IL IL187738A patent/IL187738A0/en unknown
- 2007-12-03 NO NO20076196A patent/NO20076196L/no not_active Application Discontinuation
- 2007-12-05 ZA ZA200710606A patent/ZA200710606B/xx unknown
-
2008
- 2008-01-11 EC EC2008008103A patent/ECSP088103A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20080033265A (ko) | 2008-04-16 |
| NO20076196L (no) | 2008-02-29 |
| US20100048530A1 (en) | 2010-02-25 |
| ZA200710606B (en) | 2008-12-31 |
| UY29615A1 (es) | 2007-01-31 |
| CN101223163A (zh) | 2008-07-16 |
| AU2006259894A1 (en) | 2006-12-28 |
| ECSP088103A (es) | 2008-02-20 |
| AR057383A1 (es) | 2007-12-05 |
| WO2006137793A1 (en) | 2006-12-28 |
| IL187738A0 (en) | 2008-08-07 |
| EP1896458A4 (en) | 2010-03-10 |
| EP1896458A1 (en) | 2008-03-12 |
| BRPI0611616A2 (pt) | 2011-05-31 |
| TW200726760A (en) | 2007-07-16 |
| MX2007016486A (es) | 2008-03-07 |
| CA2609990A1 (en) | 2006-12-28 |
| JP2008546770A (ja) | 2008-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007147346A (ru) | Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний | |
| RU2006125630A (ru) | Дифенилаэетидиноновые производные, обладающие активностью, ингибирующей всасывание холестерина | |
| RU2007147339A (ru) | Новые производные 2-азетидинона, полезные в лечении гиперлипидемических состояний | |
| RU2007147344A (ru) | Новые производные 2-азетидинона для лечения гиперлипидемических заболеваний | |
| RU2007147341A (ru) | Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний | |
| RU2007147340A (ru) | Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний | |
| RU2403251C2 (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 | |
| RU2397976C2 (ru) | Производные бензамидов и гетероаренов | |
| RU2007147338A (ru) | Новые производные 2-азетидинона и их применение в качестве ингибиторов всасывания холестерина для лечения гиперлипидемии | |
| RU2391346C2 (ru) | 39-дезметокси производные рапамицина | |
| RU2361870C2 (ru) | Новые кумарины, их карбоксамидные производные, способы получения, композиции и применение | |
| AR060623A1 (es) | Compuestos derivados de 2-azetidinona y un metodo de preparacion | |
| BRPI0414462A (pt) | derivados de ácido 4-(fenil-etilidenoaminóxi-propóxi)-fenil-acético e compostos relacionados como inibidores de pai-1 para o tratamento de dano do sistema fibrinolìtico e de trombose | |
| PE20040155A1 (es) | Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen | |
| RU2005118409A (ru) | Новые гидроксииндолы, их применение в качестве ингибиторов фосфодиэстеразы 4 и способ их получения | |
| RU2007139453A (ru) | Гетеробициклические ингибиторы вируса гепатита с (hcv) | |
| JP2015516420A5 (enExample) | ||
| RU2007128313A (ru) | Амиды 3-арил-3-гидрокси-2-аминопропионовой кислоты, амиды 3-гетероарил-3-гидрокси-2-аминопропионовой кислоты и родственные соединения, обладающие обезболивающим и/или иммуностимулирующим действием | |
| RU2011133128A (ru) | Противоопухолевые соединения дигидропиран-2-она | |
| EA200400994A1 (ru) | Новые 1,2,3-замещенные производные индолизина, являющиеся ингибиторами факторов роста фибробластов, способ их получения и фармацевтические композиции, содержащие их | |
| JP2018529648A5 (enExample) | ||
| PE20050160A1 (es) | 3-aminopirrolidinas como inhibidores de la captacion de monoaminas | |
| RU2012136457A (ru) | Новые композиции для уменьшения аb 42 синтеза и их применение в лечении болезни альцгеймера (ad) | |
| PE20060184A1 (es) | Derivados de imidazoles como inhibidores de la sintesis del colesterol | |
| EA200700064A1 (ru) | Способ получения эфиров 4,4-дифтор-3-оксобутановой кислоты |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20100520 |